The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review.

TitleMonoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review.
Publication TypeJournal Article
Year of Publication2018
AuthorsTsetsos, N., Goudakos J. K., Daskalakis D., Konstantinidis I., & Markou K.
JournalRhinology
Volume56
Issue1
Pagination11-21
Date Published2018 Mar 01
ISSN0300-0729
KeywordsAntibodies, Monoclonal, Chronic Disease, Endoscopy, Humans, Nasal Polyps, Quality of Life, Rhinitis, Sinusitis
Abstract

BACKGROUND: Monoclonal antibodies have been proposed as a novel therapy in patients suffering from chronic rhinosinusitis with nasal polyposis (CRSwNP). The purpose of this systematic review was to evaluate their efficacy and safety.METHODOLOGY: A literature search was performed in MEDLINE, Web of Science, the Cochrane Library and multiple trial registries followed by extensive hand-searching for the identification of relevant studies. Only randomized controlled trials (RCTs) comparing the use of monoclonal antibodies with placebo or another therapy in adult patients with CRSwNP were included.RESULTS: Anti-immunoglobin E (IgE) therapy with omalizumab was assessed in two studies, anti-interleukin (IL)-5 therapy in three studies (1 reslizumab, 2 mepolizumab) and finally anti-IL-4 and anti-IL-13 therapy in only one. With the exception of one study, biologic therapy was proved to be effective in reducing total nasal endoscopic polyp score (TPS) in treatment as compared to placebo groups. Monoclonal antibodies brought about improvement in several other outcomes, such as opacification in computed tomography (CT), quality of life measures, nasal airflow, olfaction and type 2 helper T-cell (Th2) associated biomarkers. Overall, the use of these agents was deemed safe and well-tolerated.CONCLUSIONS: This is the first systematic review showing encouraging results for the use of all three main categories of monoclonal antibodies in CRSwNP patients and highlights the need for further well-designed and with larger sample sizes RCTs.

DOI10.4193/Rhin17.156
Alternate JournalRhinology
PubMed ID29396960

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.